Eli Lilly’s anti-obesity drug Zepbound is expected to be a major cost driver for health insurers, government health programs and employers this year, according to Aon and GlobalData. The drug has shown superior efficacy in weight loss compared with Novo Nordisk’s Wegovy, suggesting it will dominate this market and potentially lead to higher health care premiums, as cost increases are projected for employer-sponsored coverage.
Full Story: Forbes (tiered subscription model) (1/1)